Podcasts about cutaneous

Hey guys, what you are about to listen to is an extremely graphic episode that will contain many scenes of gore, rape, human experimentation, honestly it will run the gambit. If you got a weak stomach, this episode might not be for you. You have been warned.  I just want to take a chance to say a big thanks to all of you guys who decided to join the patreon, you guys are awesome! Please leave a comment on this episode to let me know what more you want to hear about in the future. With all of that said and done lets jump right into it.   Where to begin with this one? Let start off with one of the major figures of Unit 731, Shiro Ishii. Born June 25th, 1892 in the village of Chiyoda Mura in Kamo District of Chiba Prefecture, Ishii was the product of his era. He came from a landowning class, had a very privileged childhood. His primary and secondary schoolmates described him to be brash, abrasive and arrogant. He was a teacher's pet, extremely intelligent, known to have excellent memory. He grew up during Japans ultra militarism/nationalism age, thus like any of his schoolmates was drawn towards the military. Less than a month after graduating from the Medical department of Kyoto Imperial University at the age of 28, he began military training as a probation officer in the 3rd regiment of the Imperial Guards division. Within 6 months he became a surgeon 1st Lt. During his postgraduate studies at Kyoto Imperial university he networked successfully to climb the career ladder. As a researcher he was sent out to help cure an epidemic that broke out in Japan. It was then he invented a water filter that could be carried alongside the troops.   He eventually came across a report of the Geneva Protocol and conference reports of Harada Toyoji as well as other military doctors. He became impressed with the potential of chemical and biological warfare. During WW1 chemical warfare had been highly explored, leading 44 nations to pass the Geneva Protocol or more specifically  “Protocol for the Prohibition of the Use in War of Asphyxiating, Poisonous or other Gases, and of Bacteriological Methods of Warfare”. Representatives from Japan were present at this conference and were involving in the drafting and signing of the Geneva Protocol, but it was not ratified in Japan at the time. Ishii's university mentor, Kiyano Kenji suggested he travel western countries and he did so for 2 years. Many nations were secretive about their research, but some places such as MIT were quite open. After his visit Ishii came to believe Japan was far behind everyone else in biological warfare research. After returning to Japan Ishii became an instructor at the Imperial Japanese Army Medical School. Japan of course lacked significant natural resources, thus it was a perfect nation to pursue biological weapons research. Ishii began lobbying the IJA, proposing to establish a military agency to develop biological weapons. One of his most compelling arguments was “that biological warfare must possess distinct possibilities, otherwise, it would not have been outlawed by the League of Nations.”   Ishii networked his way into good favor with the Minister of Health, Koizumi Chikahiko who lended his support in August of 1932 to allow Ishii to head an Epidemic Prevention Laboratory. Ishii secured a 1795 square meter complex at the Army Medical College. Yet this did not satisfy Ishii, it simply was not the type of work he wanted to do. The location of Tokyo allowed too many eyes on his work, he could not perform human experimentation. For what he wanted to do, he had to leave Japan, and in the 1930's Japan had a few colonies or sphere's of influence, the most appetizing one being Manchuria. In 1932 alongside his childhood friend Masuda Tomosada, Ishii took a tour of Harbin and he fell in love with the location.   During the 1930's Harbin was quite a cosmopolitan city, it was a major trading port and diverse in ethnicities and religions. Here there were Mongols, Russians, Chinese, Japanese, various other western groups in lesser numbers. Just about every religion was represented, it was a researcher's paradise for subjects. Ishii sought human experimentation and needed to find somewhere covert with maximum secrecy. He chose a place in the Nan Gang District of Beiyinhe village, roughly 70 kms southeast of Harbin. It was here and then he began human experimentation. One day in 1932, Ishii and the IJA entered the village and evacuated an entire block where Xuan Hua and Wu Miao intersected. They began occupying a multi-use structure that had been supporting 100 Chinese vendors who sold clothes and food to the locals. They then began drafting Chinese laborers to construct the Zhong Ma complex to house the “Togo Unit” named after the legendary admiral, Togo Heihachiro. The Chinese laborers were underpaid and under constant watch from Japanese guards, limiting their movement and preventing them from understanding what they were building, or what was occurring within the complex. The complex was built in under a year, it held 100 rooms, 3 meter high brick walls and had an electric fence surrounding the perimeter. One thousand captives at any given time could be imprisoned within the complex. To ensure absolute secrecy, security guards patrolled the complex 24/7. Saburo Endo, director of Operations for the Kwantung Army once inspected the Togo Unit and described it in his book “The Fifteen Years' Sino-Japanese War and Me”, as such:   [It was] converted from a rather large soy sauce workshop, surrounded by high rammed earth wall. All the attending military doctors had pseudonyms, and they were strictly regulated and were not allowed to communicate with the outsiders. The name of the unit was “Tōgō Unit.” One by one, the subjects of the experiments were imprisoned in a sturdy iron lattice and inoculated with various pathogenic bacteria to observe changes in their conditions. They used prisoners on death row in the prisons of Harbin for these experiments. It was said that it was for national defense purposes, but the experiments were performed with appalling brutality.The dead were burned in high-voltage electric furnaces, leaving no trace.    A local from the region added this about the complex “We heard rumors of people having blood drawn in there but we never went near the place. We were too afraid. When the construction started, there were about forty houses in our village, and a lot of people were driven out. About one person from each home was taken to work on the construction. People were gathered from villages from all around here, maybe about a thousand people in all. The only things we worked on were the surrounding wall and the earthen walls. The Chinese that worked on the buildings were brought in from somewhere, but we didn't know where. After everything was finished, those people were killed.”    Despite all the secrecy, it was soon discovered prisoners were being taken, primarily from the CCP and bandits who were being subjected to tests. One such test was to gradually drain a victim of blood to see at what point they would die. The unit drew 500 cc of blood from each prisoner every 3-5 days. As their bodies drew weaker, they were dissected for further research, the average prisoner lasted a maximum of a month. Due to the climate of Manchuria, it was soon established that finding methods to treat frostbite would benefit the Kwantung army. Ishii's team gathered human subjects and began freezing and unfreezing them. Sometimes these experiments included observing test subjects whose limbs had been frozen and severed. The Togo team reported to General Okamura Yasuji, the deputy commander in chief of the Kwantung army from 1933-1934 that the best way to treat frostbite was to soak a limb in 37 degree water. According to the testimony of a witness named Furuichi at trial done in Khabarovsk , “Experiments in freezing human beings were performed every year in the detachment, in the coldest months of the year—November, December, January and February. The experimental technique was as follows: the test subjects were taken out into the frost at about 11 o'clock at night, compelled to dip their hands into a barrel of cold water and forced to stand with wet hands in the frost for a long time. Alternatively, some were taken out dressed, but with bare feet and compelled to stand at night in the frost during the coldest period of the year. When frostbite had developed, the subjects were taken to a room and forced to put their feet in water of 5 degrees Celsius, after which the temperature was gradually increased.”   Sergeant Major Kurakazu who was with Unit 731 later on in 1940 and taken prisoner by the Soviets in 1945 stated during the Khabarovsk trial , “I saw experiments performed on living people for the first time in December 1940. I was shown these experiments by researcher Yoshimura, a member of the 1st Division. These experiments were performed in the prison laboratory. When I walked into the prison laboratory, ve Chinese experimentees were sitting there; two of these Chinese had no fingers at all, their hands were black; in those of three others the bones were visible. They had fingers, but they were only bones. Yoshimura told me that this was the result of freezing experiments.”   According to Major Karasawa during the same trial Ishii became curious about using plague as a weapon of war and captured plague infected mice to test on subjects in the Zhong Ma Complex “Ishii told me that he had experimented with cholera and plague on the mounted bandits of Manchuria during 1933-1934 and discovered that the plague was effective.”   According to Lt General Endo Saburo's diary entry on November 16th of 1933, at the Zhong Ma complex “The second squad which was responsible for poison gas, liquid poison; and the First Squad which was responsible for electrical experiments. Two bandits were used by each squad for the experiments.  Phosgene gas—5-minute injection of gas into a brick-lined room; the subject was still alive one day aer inhalation of gas; critically ill with pneumonia.  Potassium cyanide—the subject was injected with 15 mg.; subject lost consciousness approximately 20 minutes later.  20,000 volts—several jolts were not enough to kill the subject; injection of poison required to kill the subject.  5000 volts—several jolts were not enough; aer several minutes of continuous current, subject was burned to death.”    The Togo Unit established a strict security system to keep its research highly confidential. Yet in 1934, 16 Chinese prisoners escaped, compromising the Zhong Ma location. One of the guards had gotten drunk and a prisoner named Li smashed a bottle over his head and stole his keys. He freed 15 other prisoners and of them 4 died of cold, hunger and other ailments incurred by the Togo unit. 12 managed to flee to the 3rd route army of the Northeast Anti Japanese united Army. Upon hearing the horrifying report, the 3rd route army attacked the Togo unit at Beiyinhe and within a year, the Zhong Ma complex was exploded.    After the destruction of the Zhong Ma complex, Ishii needed a better structure. The Togo unit had impressed their superior and received a large budget. Then on May 30th of 1936 Emperor Hirohito authorized the creation of Unit 731. Thus Ishii and his colleagues were no longer part of the Epidemic Prevention Institute of the Army Medical School, now they were officially under the Kwantung Army as the Central Epidemic Prevention and Water Purification Department. Their new HQ was located in Pingfan, closer to Harbin. Their initial budget was 3 million yen for the personnel, 200-300 thousand yen per autonomous unit and 6 million yen for experimentation and research. Thus their new annual budget was over 10 million yen.    Pingfan was evacuated by the Kwantung army. Hundreds of families were forced to move out and sell their land at cheap prices. To increase security this time, people required a special pass to enter Pingfan. Then the airspace over the area became off-limits, excluding IJA aircraft, all violators would be shot down. The new Pingfan complex was within a walled city with more than 70 buildings over a 6 km tract of land. The complex's huge size drew some international attention, and when asked what the structure was, the scientists replied it was a lumber mill. Rather grotesquely, prisoners would be referred to as “maruta” or “logs” to keep up the charade. Suzuki, a Japanese construction company back then, worked day and night to construct the complex.    Now many of you probably know a bit about Unit 731, but did you know it's one of countless units?  The Army's Noborito Laboratory was established (1937) The Central Epidemic Prevention and Water Purification Department of the North China Army/ Unit 1855 was established (1938)  The Central Epidemic Prevention and Water Purification Department of Central China/ Unit 1644 (1939)  Thee Guangzhou Epidemic Prevention and Water Purification Department of South China Army/ Unit 8604 (1942)  The Central Epidemic Prevention and Water Purification Department of the Southern Expeditionary Army/ Unit 9620 (1942).    There were countless others, detachments included Unit 1855 in Beijing, Unit Ei 1644 in Nanjing, Unit 8604 in Guangzhou, and later Unit 9420 in Singapore. All of these units comprised Ishii's network, which, at its height in 1939, oversaw over 10,000 personnel.   Victims were normally brought to Pingfan during the dead of night within crammed freight cars with number logs on top. They were brought into the building via a secret tunnel. According to a witness named Fang Shen Yu, technicians in white lab coats handled the victims who were tied in bags. The victims included anyone charge with a crime, could be anti-japanese activity, opium smoking, espionage, being a communist, homelessness, being mentally handicap, etc. Victims included chinese, Mongolians, Koreans, White Russians, Harbin's jewish population and any Europeans accused of espionage. During the Khabarovsk trial, Major Iijima Yoshia admitted to personally subjecting 40 Soviet citizens to human experimentation. Harbin's diversity provided great research data. Each prisoner was assigned a number starting with 101 and ending at 1500. Onec 1500 was reached, they began again at 101, making it nearly impossible to estimate the total number of victims. Since the complex had been labeled a lumber mill to the locals, most did not worry about it or were too afraid to do so. The prison's warden was Ishii's brother Mitsuo who made sure to keep it all a secret.    Ethics did not exist within Ishii's network of horrors. Everything was done efficiently in the name of science. Pingfang was equipped for disposing the evidence of their work in 3 large incinerators. As a former member who worked with the incinerators recalled “the bodies always burned up fast because all the organ were gone; the bodies were empty”. Human experimentation allowed the researchers their first chance to actually examine the organs of a living person at will to see the progress of a disease. Yeah you heard me right, living person, a lot of the vivisections were done on live people. As one former researcher explained "the results of the effects of infection cannot be obtained accurately once the person dies because putrefactive bacteria set in. Putrefactive bacteria are stronger than plague germs. So, for obtaining accurate results, it is important whether the subject is alive or not." Another former researcher said this “"As soon as the symptoms were observed, the prisoner was taken from his cell and into the dissection room. He was stripped and placed on the table, screaming, trying to fight back. He was strapped down, still screaming frightfully. One of the doctors stuffed a towel into his mouth, then with one quick slice of the scalpel he was opened up." Witnesses of some of these vivisections reported that victims usually let out a horrible scream when the initial cuts were made, but that the voice stops soon after. The researchers often removed the organ of interest, leaving others in the body and the victims usually died of blood loss or because of the removed organ. There are accounts of experiments benign carried out on mothers and children, because yes children were in fact born in the facilities. Many human specimens were placed in jars to be viewed by Tokyo's army medical college. Sometimes these jars were filled with limbs or organs but some giant ones had entire bodies.   Vivisection was conducted on human beings to observe how disease affected each organ once a human dies. According to testimony given by a technician named Ogawa Fukumatsu “I participated in vivisections. I did them every day. I cannot remember the amount of people dissected. At first, I refused to do it. But then, they would not allow me to eat because it was an order; gradually I changed.” Another technician Masakuni Kuri testified  “I did vivisection at the time. Experiments were conducted on a Chinese woman with syphilis. Because she was alive, the blood poured out like water from a tap.”   A report done by Shozo Kondo studied the effects of bubonic plague on humans. The number of subjects was 57 with age ranging from toddlers to 80 years old with mixed gender. The study used fleas carrying plague that were dispersed upon the local population in June of 1940 at Changchun. 7 plague victims were Japanese residents. The report stated the plague spread because of lack of immunity by the townspeople. Subjects' survival time ranged from 2-5 days, with only 3 surviving 12, 18 and 21 days. The subjects were infected with Glandular, Cutaneous or Septicemic plague, but most had the Glandular variety.     In addition to the central units of Pingfang were others set up in Beijing, Nanjing, Guangzhou and Singapore. The total number of personnel was 20,000. These satellite facilities all had their own unique horror stories. One was located in Anda, 100km from Pingfang where outdoor tests for plague, cholera and other pathogens were down. They would expose human subjects to biological bombs, typically by putting 10-40 people in the path of a biological bomb. A lot of the research was done to see the effective radius of the bombs, so victims were placed at different distances. At Xinjing was Unit 100 and its research was done against domesticated animals, horses particularly. Unit 100 was a bacteria factory producing glanders, anthrax and other pathogens. They often ran tests by mixing poisons with food and studied its effects on animals, but they also researched chemical warfare against crops. At Guangzhou was unit 8604 with its HQ at Zhongshan medical university. It is believed starvation tests ran there, such as the water test I mentioned. They also performed typhoid tests and bred rats to spread plague. Witness testimony from a Chinese volunteer states they often dissolved the bodies of victims in acid. In Beijing was Unit 1855 which was a combination of a prison and experiment center. They ran plague, cholera and typhus tests. Prisoners were forced to ingest mixtures of germs and some were vaccinated against the ailments. In Singapore after its capture in February of 1942 there was a secret laboratory. One Mr. Othman Wok gave testimony in the 1990s that when he was 17 years old he was employed to work at this secret lab. He states 7 Chinese, Indian and Malay boys worked in the lab, picking fleas from rats and placing them in containers. Some 40 rat catchers, would haul rats to the lab for the boys to do their work. The containers with fleas went to Japanese researchers and Othman says he saw rats being injected with plague pathogens. The fleas were transferred to kerosene cans which contained dried horse blood and an unidentified chemical left to breed for weeks. Once they had plague infected fleas in large quantity Othman said "A driver who drove the trucks which transported the fleas to the railway station said that these bottles of fleas were sent off to Thailand." If this is true, it gives evidence to claims Unit 731 had a branch in Thailand as well. Othman stated he never understood or knew what was really going on at the lab, but when he read in 1944 about biological attacks on Chongqing using fleas, he decided to leave the lab. Othman states the unit was called Unit 9240.  As you can imagine rats and insects played a large role in all of this. They harvested Manchuria rat population and enlisted schoolchildren to raise them. In the 1990s the Asahi Broadcasting company made a documentary titled “the mystery of the rats that went to the continent”. It involved a small group of high school children in Saitama prefecture asked local farmers if they knew anything about rat farming during the war years. Many stated everybody back then was raising rats, it was a major source of income. One family said they had rat cages piled up in a shed, each cage built to carry 6 rat, but they had no idea what the rats were being used for. Now hear this, after the war, the US military kept these same families in business. The US army unit 406 which was established in Tokyo to research viruses wink wink, would often drive out to these farms in their american jeeps collecting rats.  Getting fleas was a much tricker task. One method was taking older Chinese prisoners and quarantining them with clothes carrying flea or flea eggs and allowing them to live in isolated rooms to cultivate more fleas. These poor guys had to live in filth and not shave for weeks to produce around 100 fleas a day. Now Unit 731 dealt with numerous diseases such as Cholera.  Some experiments used dogs to spread cholera to villages. They would steal dogs from villages, feed them pork laced with cholera germs and return them to the villages. When the disease finished incubating the dogs would vomit and other dogs would come and eat the vomit spread it more and more. The dogs were also stricken with diarrhea and the feces spread it to other dogs as well. 20% of the people in villages hit by this died of the disease. Former army captain Kojima Takeo was a unit member involved in a Cholera campaign and added this testimony "We were told that we were going out on a cholera campaign, and we were all given inoculations against cholera ten days before starting out. Our objective was to infect all the people in the area. The disease had already developed before we got there, and as we moved into the village everyone scattered. The only ones left were those who were too sick to move. The number of people coming down with the disease kept increasing. Cholera produces a face like a skeleton, vomiting, and diarrhea. And the vomiting and defecating of the people lying sick brought flies swarming around. One after the other, people died." I've mentioned it a lot, Plague was a staple of Unit 731. The IJA wanted a disease that was fast and fatal, Cholera for instance took about 20 days, plague on the other hand starts killing in 3 days. Plague also has a very long history of use going back to the medieval times. It was one of the very first diseases Ishii focused on. In october of 1940 a plague attack was conducted against the Kaimingjie area in the port city of Ningbo. This was a joint operation with Unit 731 and the Nanjing based Unit 1644. During this operation plague germs were mixed with wheat, corn, cloth scraps and cotton and dropped from the air. More than 100 people died within a few days of the attack and the affected area was sealed off from the public until the 1960s.  Another horrifying test was the frostbite experiments. Army Engineer Hisato Yoshimura conducted these types of experiments by taking prisoners outside, dipping various appendages into water of varying temperatures and allowing the limbs to freeze. Once frozen, Yoshimura would strike their affected limbs with a short stick and in his words “they would emit a sound resembling that which a board gives when it is struck”. Ice was then chipping away with the affected area being subjected to various treatments, such as being doused in water, exposed to heat and so on. I have to mentioned here, that to my shock there is film of these specific frostbite experiments and one of our animators at Kings and Generals found it, I have seen a lot of things in my day, but seeing this was absolute nightmare fuel. If you have seen the movie or series Snowpiercer, they pretty much nail what it looked like.  Members of Unit 731 referred to Yoshimura as a “scientific devil” and a “cold blooded animal” because he would conduct his work with strictness. Naoji Uezono another member of Unit 731, described in a 1980s interview a disgusting scene where Yoshimura had "two naked men put in an area 40–50 degrees below zero and researchers filmed the whole process until [the subjects] died. [The subjects] suffered such agony they were digging their nails into each other's flesh". Yoshimuras lack of any remorse was evident in an article he wrote for the Journal of Japanese Physiology in 1950 where he admitted to using 20 children and 3 day old infant in experiments which exposed them to zero degree celsius ice and salt water. The article drew criticism and no shit, but Yoshimura denied any guilt when contacted by a reporter from the Mainichi Shimbun. Yoshimura developed a “resistance index of frostbite” based on the mean temperature of 5 - 30 minutes after immersion in freezing water, the temperature of the first rise after immersion and the time until the temperature first rises after immersion. In a number of separate experiments he determined how these parameters depended on the time of day a victim's body part was immersed in freezing water, the surrounding temperature and humidity during immersion, how the victim had been treated before the immersion ("after keeping awake for a night", "after hunger for 24 hours", "after hunger for 48 hours", "immediately after heavy meal", "immediately after hot meal", "immediately after muscular exercise", "immediately after cold bath", "immediately after hot bath"), what type of food the victim had been fed over the five days preceding the immersions with regard to dietary nutrient intake ("high protein (of animal nature)", "high protein (of vegetable nature)", "low protein intake", and "standard diet"), and salt intake. Members of Unit 731 also worked with Syphilis, where they orchestrated forced sex acts between infected and noninfected prisoners to transmit the disease. One testimony given by a prisoner guard was as follows “Infection of venereal disease by injection was abandoned, and the researchers started forcing the prisoners into sexual acts with each other. Four or five unit members, dressed in white laboratory clothing completely covering the body with only eyes and mouth visible, rest covered, handled the tests. A male and female, one infected with syphilis, would be brought together in a cell and forced into sex with each other. It was made clear that anyone resisting would be shot.” After victims were infected, they would be vivisected at differing stages of infection so that the internal and external organs could be observed as the disease progressed. Testimony from multiple guards blamed the female victims as being hosts of the diseases, even as they were forcibly infected. Genitals of female prisoners were infected with syphilis and the guards would call them “jam filled buns”. Even some children were born or grew up in the walls of Unit 731, infected with syphilis. One researcher recalled “one was a Chinese women holding an infant, one was a white russian woman with a daughter of 4 or 5 years of age, and the last was a white russian women with a boy of about 6 or 7”. The children of these women were tested in ways similar to the adults.  There was also of course rape and forced pregnancies as you could guess. Female prisoners were forced to become pregnant for use in experiments. The hypothetical possibility of transmission from mother to child of diseases, particularly syphilis was the rationale for the experiments. Fetal survival and damage to the womans reproductive organs were objects of interest. A large number of babies were born in captivity and there had been no accounts of any survivor of Unit 731, children included. It is suspected that the children of the female prisoners were killed after birth or aborted. One guard gave a testimony “One of the former researchers I located told me that one day he had a human experiment scheduled, but there was still time to kill. So he and another unit member took the keys to the cells and opened one that housed a Chinese woman. One of the unit members raped her; the other member took the keys and opened another cell. There was a Chinese woman in there who had been used in a frostbite experiment. She had several fingers missing and her bones were black, with gangrene set in. He was about to rape her anyway, then he saw that her sex organ was festering, with pus oozing to the surface. He gave up the idea, left and locked the door, then later went on to his experimental work.” In a testimony given on December 28 by witness Furuichi during the Khabarovsk Trial, he described how “a Russian woman was infected with syphilis to allow the scientists to and out how to prevent the spread of the disease.  Many babies were born to women who had been captured and become experimental subjects. Some women were kidnapped while pregnant; others became pregnant aer forced sex acts in the prisons, enabling researchers to study the transmission of venereal disease   Initially Unit 731 and Unit 100 were going to support Japan's Kantokuen plan. The Kantokuen plan an operation plan to be carried out by the Kwantung army to invade the USSR far east, capitalizing on the success of operation barbarossa. Unit 731 and 100 were to prepare bacteriological weapons to help the invasion. The plan was created by the IJA general staff and approved by Emperor Hirohito. It would have involved three-steps to isolate and destroy the Soviet Army and occupy the eastern soviet cities over the course of 6 months. It would have involved heavy use of chemical and biological weapons. The Japanese planned to spread disease using three methods; direct spraying from aircraft, bacteria bombs and saboteurs on the ground. This would have included plague, cholera, typhus and other diseases against troops, civilian populations, livestocks, crops and water supplies. The main targets were Blagoveshchensk, Khabarovsk, Voroshilov, and Chita. If successful the Soviet Far East would be incorporated into Japan's greater east asia co-prosperity sphere. Within Kantokuen documents, Emperor Hirohtio instructed Ishii to increase production rate at the units, for those not convinced Hirohito was deeply involved in some of the worst actions of the war. Yet in the end both Emperor Hirohito and Hideki Tojo pulled their support for the invasion of the USSR and opted for the Nanshin-ron strategy instead.    On August 9th of 1945 the Soviet Union declared war on Japan and invaded Manchuria. In response, the Japanese government ordered all research facilities in Manchuria to be destroyed and to erase all incriminating materials. A skeleton crew began the liquidation of unit 731 on August 9th or 10th, while the rest of the unit evacuated. All test subjects were killed and cremated so no remains would be found. The design of the facilities however, made them hard to destroy via bombing, several parts of the buildings left standing when the Soviets arrived. While most of the unit's staff managed to escape, including Ishii, some were captured by the soviets. Some of these prisoners told the Soviets about the atrocities committed at Pingfang and Changchun. At first the claims seemed so outrageous, the Soviets sent their own Biological Weapons specialists to examine the ruins of Ping Fang. After a thorough investigation, the Soviet experts confirmed the experiments had been done there. The real soviet investigation into the secrets of Unit 731 and 100 began in early 1946, thus information was not readily available during the Tokyo Tribunal. Both the Americans and SOviets had collected evidence during the war that indicated the Japanese were in possession of bacteriological weapons though. Amongst the 600,000 Japanese prisoners of war in the USSR, Major General Kiyoshi Kawashima and Major Tomoio Karasawa would become essential to uncovering the Japanese bacteriological warfare secrets and opening the path to hold the Khabarovsk trial. The Soviets and Americans spent quite a few years performing investigations, many of which led to no arrests. The major reason for this was similar to Operation Paperclip. For those unaware, paperclip was a American secret intelligence program where 1600 German scientists were taken after the war and employed, many of whom were nazi party officials. The most famous of course was Wernher von Braun. When the Americans looked into the Japanese bacteriological work, they were surprised to find the Japanese were ahead of them in some specific areas, notably ones involving human experimentation. General Charles Willoughby of G-2 american intelligence called to attention that all the data extracted from live human testing was out of the reach of the USA. By the end of 1947, with the CCP looking like they might defeat Chiang Kai-Shek and the Soviet Union proving to be their new enemy, the US sought to form an alliance with Japan, and this included their Bacteriological specialists. From October to December, Drs Edwin Hill and Joseph Victor from Camp Detrick were sent to Tokyo to gather information from Ishii and his colleagues. Their final conclusion laid out the importance of continuing to learn from the Japanese teams, and grant them immunity. The British were also receiving some reports from the Americans about the Japanese Bacteriological research and human experimentation. The British agreed with the Americans that the information was invaluable due to the live human beings used in the tests. The UK and US formed some arrangements to retain the information and keep it secret. By late 1948 the Tokyo War Crimes Trial was coming to an end as the cold war tension was heating up in Korea, pushing the US more and more to want to retain the information and keep it all under wraps.  With formal acceptance, final steps were undertaken, much of which was overseen by General Douglas MacArthur. On May 6, 1947, Douglas MacArthur wrote to Washington that "additional data, possibly some statements from Ishii probably can be obtained by informing Japanese involved that information will be retained in intelligence channels and will not be employed as 'War Crimes' evidence.” Ishii and his colleagues received full immunity from the Tokyo War Crimes Trial. Ishii was hired by the US government to lecture American officers at Fort Detrick on bioweapons and the findings made by Unit 731. During the Korean War Ishii reportedly traveled to Korea to take part in alleged American biological warfare activities. On February 22nd of 1952, Ishiiwas explicitly named in a statement made by the North Korean FOreign Minister, claiming he along with other "Japanese bacteriological war criminals had been involved in systematically spreading large quantities of bacteria-carrying insects by aircraft in order to disseminate contagious diseases over our frontline positions and our rear". Ishii would eventually return to Japan, where he opened a clinic, performing examinations and treatments for free. He would die from laryngeal cancer in 1959 and according to his daughter became a Roman Catholic shortly before his death.  According to an investigation by The Guardian, after the war, former members of Unit 731 conducted human experiments on Japanese prisoners, babies, and mental patients under the guise of vaccine development, with covert funding from the U.S. government. Masami Kitaoka, a graduate of Unit 1644, continued performing experiments on unwilling Japanese subjects from 1947 to 1956 while working at Japan's National Institute of Health Sciences. He infected prisoners with rickettsia and mentally ill patients with typhus. Shiro Ishii, the chief of the unit, was granted immunity from prosecution for war crimes by American occupation authorities in exchange for providing them with human experimentation research materials. From 1948 to 1958, less than five percent of these documents were transferred to microfilm and stored in the U.S. National Archives before being shipped back to Japan.

In this episode of the Oncology Brothers podcast, we are joined by Dr. Omid Hamid, a melanoma specialist from Cedars-Sinai, to explore the current treatment landscape of cutaneous melanoma. We covered a wide range of topics, including: •⁠  ⁠The standard of care for early-stage melanoma, including wide local excision and sentinel lymph node evaluation. •⁠  ⁠The role of adjuvant immunotherapy and BRAF/MEK inhibitors for high-risk patients. •⁠  ⁠Insights into neoadjuvant treatment options for resectable disease, including recent trial data from NADINA and SWOG S1808. •⁠  ⁠The importance of next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) in treatment planning and monitoring. •⁠  ⁠The evolving treatment paradigm for metastatic melanoma, including the use of dual checkpoint inhibitors and BRAF/MEK inhibitors. Join us as we discuss the latest advancements in melanoma treatment and the critical role of patient education and shared decision-making in oncology care. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more episodes on treatment algorithms, new FDA approvals, and conference highlights! #Melanoma #Immunotherapy #BRAF #ctDNA #Neoadjuvant #OncologyBrothers

Please visit answersincme.com/860/TSG to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses evidence-based insights that inform the practical integration of adjuvant immunotherapy regimens into cutaneous squamous cell carcinoma (CSCC) care, based on available clinical data. Upon completion of this activity, participants should be better able to: Review the rationale for immunotherapy in the adjuvant treatment of patients with high-risk resected cutaneous squamous cell carcinoma (CSCC); Summarize the latest clinical trial data evaluating adjuvant immunotherapy in high-risk CSCC; and Outline evidence-based, multidisciplinary strategies to optimize the care of patients with high-risk CSCC in the adjuvant setting.

Mycosis fungoides - a term that is both misleading and redundant. It represents just one aspect of the often complex world of cutaneous T-cell lymphoma. When should clinicians suspect cutaneous T-cell lymphoma? How is it accurately diagnosed? What treatment options are available? In this episode, dermatologists Dr Friyana Bhabha and A/Prof Aaron Robinson provide expert insights into these questions.See omnystudio.com/listener for privacy information.

Dr. Brooke Britton answers Lou's question about his dog's cutaneous hemangiosarcoma. Learn about the risks of recurrence, treatment options, and proactive steps to monitor your dog for future tumors. Dr. Britton also discusses the breeds most at risk, the role of sun exposure, and whether supplements like Yunnan Baiyao might help. What You'll Learn: • What is cutaneous hemangiosarcoma, and how does it differ from other forms? • The importance of surgical margins in preventing recurrence. • How to monitor for new lumps or bumps in predisposed breeds. • When chemotherapy might be needed for more invasive tumors. • Tips for sun safety and preventative care for your dog. Your Voice Matters! If you have a question for our team, or if you want to share your own hopeful dog cancer story, we want to hear from you! Go to https://www.dogcancer.com/ask to submit your question or story, or call our Listener Line at +1 808-868-3200 to leave a question. Related Videos: https://www.youtube.com/watch?v=eusVRp6U0Cs https://www.youtube.com/watch?v=eUP3HcW1x-M https://www.youtube.com/watch?v=-D2zBtfRIEU Related Links: Our article on hemangiosarcoma: https://www.dogcancer.com/articles/types-of-dog-cancer/hemangiosarcoma-in-dogs/ Chapters: 00:00 Introduction 00:45 Lou's Question: Will it come back? 01:45 Dr. Britton's Insights: Factors influencing recurrence risks. 03:15 Breeds at Risk: Lightly pigmented and thin-coated dogs. 04:45 Prevention Tips: Sun safety and monitoring new lumps. 06:00 Supplements: Does Yunnan Baiyao help? 09:00 Treatment Options: Surgery, chemotherapy, and more. 10:30 Metastasis Risks: Where and how it spreads. 13:00 Genetic Predispositions: Understanding the bigger picture. 14:30 Closing Thoughts: Key takeaways for proactive care. Get to know Dr. Brooke Britton: https://www.dogcancer.com/people/brooke-britton-dvm-dacvim-oncology/ For more details, articles, podcast episodes, and quality education, go to the episode page: https://www.dogcancer.com/podcast/ Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, we review the high-yield topic of⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Cutaneous and Subcutaneous Mycoses⁠ ⁠⁠⁠⁠⁠⁠⁠⁠from the Microbiology section.Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets

The incidence and prevalence of cutaneous melanoma in the US and worldwide have increased over the last 5 decades. JAMA Review Author John Kirkwood, MD, discusses the epidemiology, risk factors, treatment, and prevention of melanoma with JAMA Deputy Editor Kristin Walter, MD, MS. Related Content: Cutaneous Melanoma ----------------------------------- JAMA Editors' Summary

In today's episode, supported by Immatics, we spoke with Jason Luke, MD, about the development of the PRAME-directed T-cell receptor (TCR) T-cell therapy IMA203 in the ongoing phase 3 SUPRAME trial (NCT06743126) in patients with previously treated, unresectable or metastatic cutaneous melanoma. In our conversation, Dr Luke discussed the rationale for evaluating IMA203 in patients with cutaneous melanoma, the mechanism of action of this novel drug, the design of this study, earlier data that support the continued investigation of this agent in this population, and what these findings may mean for the future of TCR therapy in melanoma.

NAC (N-acetylcysteine) in kids -Vitamin D for sunburn - Imiquimod for PGs -How to prevent bone issues in patients on steroids - Cutaneous extramedullary plasmacytoma -DRESS by drug -Learn more about the U of U Dermatology ECHO model!physicians.utah.edu/echo/dermatology-primarycareWant to donate to the cause? Do so here!
Donate to the podcast: uofuhealth.org/dermasphere
Check out our video content on YouTube:
www.youtube.com/@dermaspherepodcast
and VuMedi!: www.vumedi.com/channel/dermasphere/
The University of Utah's Dermatology
ECHO: ⁠physicians.utah.edu/echo/dermatology-primarycare -
⁠ Connect with us!
- Web: ⁠dermaspherepodcast.com/⁠ - Twitter: @DermaspherePC
- Instagram: dermaspherepodcast
- Facebook: www.facebook.com/DermaspherePodcast/
- Check out Luke and Michelle's other podcast,
SkinCast! ⁠healthcare.utah.edu/dermatology/skincast/⁠ Luke and Michelle report no significant conflicts of interest… BUT check out our
friends at:
- ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge)
- ⁠www.levelex.com/games/top-derm⁠ (A free dermatology game to learn
more dermatology!

In this episode: Photosensitive reactions often appear as sunburn-like rashes on exposed skin after using certain oral or topical drugs. Diagnosis is based on timing, pattern of rash, and differentiating between phototoxic and photoallergic types. Management involves sun protection, reviewing medications, and referring to dermatologist if cases are recurrent or unusual. Host: Dr David Lim, GP and Medical Educator Expert: Dr Philip Tong, Dermatologist Total time: 24 mins Register for our fortnightly FREE WEBCASTS Every second Tuesday | 7:00pm-9:00pm AESTSee omnystudio.com/listener for privacy information.

In this episode of Cutaneous Miscellaneous, host Nicholas Brownstone, MD, is joined by Ryan Svoboda, MD, for an in-depth review of cutaneous lymphomas. They begin with a boards review of the four primary cutaneous B-cell lymphomas—two indolent (follicle center, marginal zone) and two aggressive (diffuse large B-cell, intravascular B-cell). The discussion covers prognostic differences, biopsy strategies, key immunostains, helpful mnemonics for BCL markers, and notable associations such as Borrelia infection. In the main segment, the focus shifts to cutaneous T-cell lymphomas, particularly mycosis fungoides. Dr Svoboda shares diagnostic challenges, strategies to improve biopsy yield, and a practical scoring algorithm to interpret inconclusive pathology reports. They also review tips for diagnosing Sézary syndrome and highlight relevant NCCN guidelines. Tune in to the full episode for high-yield insights on recognizing, diagnosing, and managing both B-cell and T-cell cutaneous lymphomas in clinical practice.

In this episode, we review the high-yield topic of⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Cutaneous Warts (Verrucae) from the Dermatology section.Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets

「メンソール」をおでこに塗ると頭痛に効く？　35人を対象に実験　2010年の研究結果。　イランのShiraz University of Medical Sciencesなどに所属する研究者らが2010年に発表した論文「Cutaneous application of menthol 10％ solution as an abortive treatment of migraine without aura: a randomised, double-blind, placebo-controlled, crossed-over study」は、ペパーミントの主要成分であるメンソール（メントール）が片頭痛に効くかを調査した研究報告だ。

Please visit answersincme.com/VJW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in cutaneous oncology discuss the role of emerging immunotherapeutic strategies in treating resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Review the current guideline-recommended use of immunotherapies for the management of resectable CSCC; Identify clinical factors that will guide the use of immunotherapeutic approaches for patients with resectable CSCC; Outline proactive strategies to enhance the benefit-to-risk profile of immunotherapy for patients with resectable CSCC; and Describe the evolving role of novel applications of immunotherapy in the treatment of resectable CSCC. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/VJW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in cutaneous oncology discuss the role of emerging immunotherapeutic strategies in treating resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Review the current guideline-recommended use of immunotherapies for the management of resectable CSCC; Identify clinical factors that will guide the use of immunotherapeutic approaches for patients with resectable CSCC; Outline proactive strategies to enhance the benefit-to-risk profile of immunotherapy for patients with resectable CSCC; and Describe the evolving role of novel applications of immunotherapy in the treatment of resectable CSCC. This activity is intended for US healthcare professionals only.

In this episode: Accurate diagnosis is crucial First-line treatments include cryotherapy and topical agents Set realistic expectations and educate patients Consider patient factors (eg. occupation, immunosuppression) Escalate to specialist care when indicated Host: Dr David Lim, GP and Medical Educator Expert: Dr Philip Tong, Dermatologist Total time: 25 mins Register for our fortnightly FREE WEBCASTS Every second Tuesday | 7:00pm-9:00pm AEST Click here to register for the next oneSee omnystudio.com/listener for privacy information.

In today's episode, supported by Immatics, we had the pleasure of speaking with Justin Moser, MD, about the ongoing phase 3 SUPRAME trial investigating the PRAME-directed T-cell receptor T-cell therapy IMA203 vs treatment of physician's choice in patients with previously treated, unresectable or metastatic cutaneous melanoma. Dr Moser is an associate clinical investigator, a melanoma and cutaneous oncology specialist, and a phase 1 trialist at HonorHealth Research Institute in Scottsdale, Arizona; as well as a research associate professor at the Arizona State University School of Medicine and Advanced Medical Engineering. In our exclusive interview, Dr Moser discussed the unique mechanism of action of IMA203, previously reported phase 1 data with this agent in patients with melanoma, and the design and potential future implications of SUPRAME. 

Discussion of the diagnosis, management, and latest insights into cutaneous manifestations of SLE. Panelists: Dr. Victoria P. Werth, Dr. Matilda Nicholas; Dr. Anthony Fernandez; and, Dr. Christopher Richardson.

Melanoma treatment has advanced significantly over the past decade, and it continues to evolve. In this special Melanoma Monday episode, we are joined by Kendra Rodriguez, PharmD, PGY2 Oncology Pharmacy Resident at UW Medical Center / Fred Hutchinson Cancer Center, to explore where we are now in the treatment landscape—and what's on the horizon.Kendra walks through recent data from the NADINA and SWOG S1801 trials, and shares how care teams can start preparing for the shift in management to the neoadjuvant setting. You'll hear what it takes to manage complex therapies for resectable cutaneous melanoma, and how to engage patients through thoughtful communication and collaboration.CE Activity Description:The purpose of this CE activity is to describe the pathophysiology and literature behind the shift of pharmacotherapeutic management to the neoadjuvant setting in resectable cutaneous melanoma. As novel mechanisms have been sought after and approved within this disease state, attention will be given to assess the clinical utility of the first-in-class tumor-infiltrating lymphocyte, lifileucel, in addition to its logistical considerations requiring multidisciplinary coordination.Learning Objectives:Summarize the pathophysiology behind neoadjuvant treatment in cutaneous melanoma and the literature supporting its useDiscuss the novel agent lifileucel for its efficacy in cutaneous melanoma treatment and the logistics related to its useDisclosures:No relevant financial relationships for the following faculty and reviewers:• Kendra Gee-Rodriguez, PharmD• Ginger Blackmon, PharmD• Daisy Doan, PharmDClaim credit: https://www.lecturepanda.com/r/CutaneousMelanoma

interviewed by Mona Sadeghpour, MD, FAAD

Welcome to the fourth episode of ASTCT Talks' exclusive 8-part series, supported by an educational grant from Sanofi US. In this episode, former ASTCT President Dr. Corey Cutler sits down with Dr. Connie R. Shi from the Cutaneous Oncology Program at Dana-Farber Cancer Institute. They discuss Dr. Shi's recent article, Cutaneous Chronic Graft-Versus-Host Disease: Clinical Manifestations, Diagnosis, Management, and Supportive Care.Tune in as they explore the complexities of cutaneous GVHD, including acute and chronic presentations, diagnostic challenges and skin-directed treatment strategies such as topical steroids and phototherapy. They also cover key considerations for recognizing and diagnosing cutaneous GVHD in patients of all skin tones and managing long-term complications like skin cancer risk.

Derm and mental health - with Cutaneous Miscellaneous! -Melasma treatments - with Dr. Carson Jessop! -Congenital nevi in infants -HS increased risk of VTE -Join Luke's CME experience on Jak inhibitors! rushu.gathered.com/invite/ELe31Enb69Register for the U of U Practical Derm course!medicine.utah.edu/dermatology/educ…nities/practicalLearn more about the U of U Dermatology ECHO model!physicians.utah.edu/echo/dermatology-primarycareWant to donate to the cause? Do so here!
Donate to the podcast: uofuhealth.org/dermasphere
Check out our video content on YouTube:
www.youtube.com/@dermaspherepodcast
and VuMedi!: www.vumedi.com/channel/dermasphere/
The University of Utah's Dermatology
ECHO: ⁠physicians.utah.edu/echo/dermatology-primarycare -
⁠ Connect with us!
- Web: ⁠dermaspherepodcast.com/⁠ - Twitter: @DermaspherePC
- Instagram: dermaspherepodcast
- Facebook: www.facebook.com/DermaspherePodcast/
- Check out Luke and Michelle's other podcast,
SkinCast! ⁠healthcare.utah.edu/dermatology/skincast/⁠ Luke and Michelle report no significant conflicts of interest… BUT check out our
friends at:
- ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge)
- ⁠www.levelex.com/games/top-derm⁠ (A free dermatology game to learn
more dermatology!

A Cutaneous T-cell Lymphoma (CTCL) diagnosis can raise many questions, from understanding symptoms to exploring treatment options.  In this episode,… The post Cutaneous T-Cell Lymphoma (CTCL): From Diagnosis to Innovation first appeared on The Bloodline with LLS.

In this episode, host Alyssa Watson, DVM, welcomes Charlie Pye, DVM, DVSc, DACVD, to talk about her recent Clinician's Brief article, “Cutaneous Lymphoma in an American Pit Bull Terrier Crossbreed.” Dr. Pye covers all the essential background for cutaneous lymphoma, which can mimic many other skin diseases. She also gives practical tips for performing skin biopsies, runs through treatment options, and even negotiates the challenging terminology connected to this disease (mycosis fungoides?!).Resource:https://www.cliniciansbrief.com/article/lymphoma-treatment-lymph-nodes-dogContact:podcast@instinct.vetWhere To Find Us:Website: CliniciansBrief.com/PodcastsYouTube: Youtube.com/@clinicians_briefFacebook: Facebook.com/CliniciansBriefLinkedIn: LinkedIn.com/showcase/CliniciansBrief/Instagram: @Clinicians.BriefX: @CliniciansBriefThe Team:Alyssa Watson, DVM - HostAlexis Ussery - Producer & Multimedia Specialist

Which of the following conditions is MOST likely present in a patient with exaggerated cutaneous reflexes? Find it all out in the podcast!  Be prepared for the NPTE so that you can pass with flying colors! Check out www.ptfinalexam.com/podcast for more information and to stay up-to-date with our latest courses and projects.  #Npte #PT /#ptboards #crushtheNPTE #study #studygram #spt #ptstudent #ptlife #sptprobs #physicaltherapystudent #physicaltherapy #physio #physiotherapist #ptlife #ptstudentstudy

Jaehyuk (Jae) Choi, MD, Northwestern University Feinberg School of Medicine, Chicago, IL Recorded on January 7, 2025 Jaehyuk (Jae) Choi, MD Jack W. Graffin Associate Professor of Dermatology and of Biochemistry and Molecular Genetics Northwestern University Feinberg School of Medicine Chicago, IL In this episode, Dr. Jaehyuk Choi from Northwestern University, explores Cutaneous T-Cell Lymphoma (CTCL), covering key diagnostic tools, emerging therapies, and the importance of a multidisciplinary team approach. He delves into effective symptom management, including the psychosocial impact of pruritus, and discusses the latest ongoing research. Additionally, Dr. Choi highlights disparities in diagnosis, treatment access, and patient outcomes. Tune in today to gain valuable insights on this complex diagnosis! This episode is supported by Kyowa Kirin, Inc.

In this week's episode we'll learn more about an experimental regimen for classical Hodgkin lymphoma that combines brentuximab vedotin, nivolumab, and chemotherapy; a possible role for type 1 interferon signaling in developing autoantibodies to red blood cells in sickle cell disease; and how genomic alterations affecting class I human leukocyte antigen molecules may affect patients with cutaneous T-cell lymphoma. Featured Articles:Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphomaIFN-I promotes T-cell–independent immunity and RBC autoantibodies via modulation of B-1 cell subsets in murine SCDGenetic alteration of class I HLA in cutaneous T-cell lymphoma

In this JCO Article Insights episode, Giselle de Souza Carvalho provides a summary on  "Navigating Treatment Pathways in Metastatic Hormone Receptor–Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted Therapies" by Bhardwarj, et al and "US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA/AKT1/PTEN Alterations" by Dilawari et al published in the Journal of Clinical Oncology.  TRANSCRIPT Giselle Carvalho: Hello and welcome to JCO Article Insights episode for the December issue of the Journal of Clinical Oncology. I'm your host Giselle Carvalho, Medical Oncologist in Brazil focusing on breast cancer and melanoma skin cancers and one of the ASCO Editorial Fellows at JCO this year. Today, I will be discussing two articles. The first one is “Navigating Treatment Pathways in Metastatic Hormone Receptor–Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted Therapies,” and the second one is the “US FDA Approval Summary on Capivasertib with Fulvestrant  for HR-positive HER2-negative Locally Advanced or Metastatic Breast Cancer with PIK3CA/AKT1/PTEN Alteration.”  As we know, 65% to 70% of all breast cancers are HR-positive HER2-negative and this is also the most common subtype of metastatic breast cancer. The current standard of care for frontline therapy of patients with luminal metastatic disease is a CDK4/6 inhibitor in combination with endocrine therapy. However, as new endocrine and targeted therapies gain approval, choosing the best systemic therapy upon disease progression after frontline therapy is a topic of ongoing debate. Nearly 40 to 50% of HR-positive breast cancers have actionable genomic alterations and molecular testing should be a routine recommendation for patients with metastatic HR-positive HER2-negative disease. This can be performed repeating tissue biopsy at the time of progression or from archival tissue. Treatment options after progression on CDK4/6 inhibitors include alpelisib in combination with fulvestrant in patients with PIK3CA mutant tumors as seen in the SOLAR-1 trial, or capivasertib with fulvestrant in patients with a tumor mutation in (PI3K)–AKT–PTEN pathway as seen in the CAPItello-291 study, which will be discussed further.  In approximately 30% of patients, progression on frontline endocrine plus CDK4/6 inhibitor treatment is caused by endocrine resistance, frequently involving activating mutations in ESR1. For those tumors, elacestrant, an oral SERD is an option as demonstrated in the EMERALD trial. For patients with a BRCA mutation, PARP inhibitors represent another option. If no mutations are detected, everolimus, an mTOR inhibitor, can be used based on the BOLERO-2 results. The phase 2 MAINTAIN and PACE trials, along with the phase 3 postMONARCH trial support changing the endocrine therapy backbone with or without switching the CDK4/6 inhibitor. In less resourced areas, fulvestrant monotherapy is still an option to delay cytotoxic chemotherapy, though its efficacy is limited when used as a single agent. Finally, after progression on at least one line of chemotherapy, antibody drug conjugates including sacituzumab govitecan or trastuzumab deruxtecan may be an option.  Now focusing on the PI3K AKT PTEN signaling pathway, activating mutations in PIK3CA and AKT1 and inactivating alterations in PTEN occur in approximately half of luminal breast cancers. In June 2023, the CAPItello-291 trial was published and treatment with fulvestrant plus capivasertib, a PTEN AKT inhibitor, demonstrated a 3.6 month PFS benefit compared to fulvestrant alone, regardless of the presence of AKT pathway alterations. However, for those with tumors without AKT pathway alteration, an exploratory analysis showed that although there was a numerical improvement in PFS, it did not meet statistical significance, indicating that the biomarker positive population primarily drove the positive results noted in the overall population. Therefore, capivasertib plus fulvestrant was approved by the US FDA in November 2023 exclusively for patients with PI3K/AKT1/PTEN tumor alterations after progression on an aromatized inhibitor with or without a CDK4/6 inhibitor. The approved schedule of capivasertib is slightly different from that of other agents used in breast cancer. It is 400 milligrams taken orally twice a day for four days per week every week in a 28-day cycle in combination with fulvestrant. Diarrhea, rash and hyperglycemia were the most commonly reported grade three or four adverse events in the interventional group. I would like to highlight that even though the CAPItello trial excluded patients with glycosylated hemoglobin levels higher than 8% or those diagnosed with diabetes who required insulin, hyperglycemia occurred in 19% of biomarker positive patients treated with capivasertib, with nearly 2% of this population experiencing grade 3 or 4 hyperglycemia and some patients experiencing life threatening outcomes such as diabetic ketoacidosis.  By way of comparison, hyperglycemia of any grade was three times higher with alpelisib therapy in the SOLAR-1 trial, occurring in 64% of the patients and grade three or higher hyperglycemia was seen in 37% of the patients. Diarrhea was the most common treatment related adverse event experienced by 77% of the biomarker positive population. Prompt use of the antidiarrheal drugs when needed, such as loperamide must be encouraged as untreated diarrhea can lead to dehydration and renal injury. Cutaneous rash occurred in 56% of the biomarker positive population in the interventional group and 15% experienced a grade 3 or 4 rash. Nearly half of the patients with cutaneous adverse reactions required treatment and this was the leading reason for dose reduction of capivasertib.  In the biomarker positive population, the improvement in medium PFS were 4.3 months by investigator assessment. Overall survival data from the CAPItello-291 trial is still immature, but quality of life data was recently published in September this year and was assessed by the 30 item QLQ C30 questionnaire and the QLQ BR23, the breast module. According to Oliveira et al, global health status and quality of life were maintained for a longer period with capivasertib fulvestrant than with placebo fulvestrant except for symptoms of diarrhea which were significantly worse in the capivasertib group. The median time of deterioration of global health status and quality of life was twice as long in the capivasertib group being almost 25 months versus 12 months in the placebo fulvestrant group. These data reinforced the use of capivasertib in combination with fulvestrant for the treatment of HR-positive HER2-negative advanced breast cancer patients with PIK3CA/AKT1/PTEN tumor alterations who have progressed after an aromatase inhibitor-based therapy with or without a CDK4/6 inhibitor.  Thank you for listening to JCO Article Insights. This is Giselle Carvalho. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts. See you next time.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.  

Nail Discoloration following the Chronic use of Skin-Depigmenting Creams. Bandara M. Liyanage A. Cureus. 2024 Aug 25; 16(8):e67770Nail Pigmentation May Be an Early Sign of Minocycline Associated Cutaneous Pigmentation: A Systemic Review. Axler E, Malik S, Lu A, Hong S, Desai AD, Malik S, Lipner SR. JAAD. 2024 Aug 26:S0190-9622(24)

Welcome to this month's P4A Let's Talk Rare podcast episode by Partners4Acess. Today, Georgie and Owen are joined by Leonard Mazur, CEO of Citius Pharmaceuticals, to discuss their innovative therapy, Lymphir, for cutaneous T-cell lymphoma (CTCL). Leonard shares his journey with Citius, from its founding in 2013 to the recent resubmission of Lymphirto the FDA, and discusses the drug's potential to alleviate severe itching for the 21,000 annual CTCL patients in the U.S. The conversation also covers Citius's commercialisation plans and ongoing trials exploring Lymphir's use for other conditions. Join Georgie, Leonard, and co-host Owen for an insightful discussion on how Citius is committed to improving patient quality of life through groundbreaking treatments! Leonard explains how Citius acquired Lymphir in 2021, a drug facing regulatory challenges that they've addressed for FDA resubmission, with potential approval expected. They discuss Lymphir's benefits, especially for CTCL patients, including its potential to relieve severe itching and outline the company's commercialisation plans with Eversana. Leonard emphasises the team's extensive expertise as vital to navigating the regulatory process. They also explore Lymphir's off-label potential for other cancers, with ongoing trials at major universities. The conversation closes on the rewarding impact of pharmaceutical work on patient lives, underscoring Citius's commitment to addressing unmet medical needs through innovative treatments. Leonard Mazur Bio: Leonard Mazur is a seasoned entrepreneur and executive with over five decades of experience in the pharmaceutical industry. He is known for his skill in founding and growing multiple healthcare companies. Currently CEO of Citius Pharmaceuticals, Leonard previously co-founded Leonard-Meron Biosciences and Akrimax Pharmaceuticals. He also led Triax Pharmaceuticals as COO, specialising in dermatology, and successfully sold his dermatological company, Genesis Pharmaceuticals, to Pierre Fabre in 2003. His extensive background spans roles in sales, marketing, and business development at Medicis, ICN, Knoll Pharma, and Cooper Labs. Born in Germany, Mazur holds an MBA from Temple University, where he also earned his undergraduate degree. He is an Ellis Island Medal of Honor recipient. Episode Resources: Leonard Mazur on LinkedIn Citius Pharmaceuticals Website Owen Bryant on LinkedIn Georgina Rack on LinkedIn Partners4Access Website  P4A Let's Talk Rare podcast on Apple Podcasts

Please visit answersincme.com/JZC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses the use of immunotherapy in advanced, unresectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Review current evidence-based recommendations informing the treatment of patients with unresectable, locally advanced, recurrent, or metastatic CSCC; Describe the clinical profiles of immunotherapies for the treatment of patients with unresectable, locally advanced, recurrent, or metastatic CSCC; and Outline potential considerations to optimize outcomes for patients with unresectable, locally advanced, recurrent, or metastatic CSCC who are on immunotherapies.

Please visit answersincme.com/JZC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses the use of immunotherapy in advanced, unresectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Review current evidence-based recommendations informing the treatment of patients with unresectable, locally advanced, recurrent, or metastatic CSCC; Describe the clinical profiles of immunotherapies for the treatment of patients with unresectable, locally advanced, recurrent, or metastatic CSCC; and Outline potential considerations to optimize outcomes for patients with unresectable, locally advanced, recurrent, or metastatic CSCC who are on immunotherapies.

Todd Cartee, MD interviewed by Carlos A. Garcia, MD

Happy Halloween!I asked for your spooky derm concerns and you delivered! Check out our top 5 sppoookkkyyy derm tips on this week's episode of The Derm Vet podcast.1. Combining immunosuppressive drugs2. Feline otitis3. Cutaneous lymphoma4. Missteps that can haunt you5. Pseudomonas otitisTIMESTAMPS00:00 Intro01:08 Concern with Combining Immunosuppressive Medications05:46 Treating Feline Otitis08:11 Cutaneous Lymphoma10:25 What is a common misstep that can haunt a practitioner?14:28 Pseudomonas Otitis16:42 Outro

Today we focus on the skin, with a wide ranging conversation featuring Northwestern Department of Dermatology's, Murad Alam, MD. Dr. Alam discusses aging, the role of UV exposure, skin cancer types and treatments, including Mohs surgery, and the latest in skin tightening and fillers. We also cover recent advancements in AI for skin cancer detection, the safety of sunscreen ingredients, and the potential of laser therapy and noninvasive procedures in aesthetic medicine.Dr. Alam is Vice Chair, Chief of Cutaneous and Aesthetic Surgery, and a professor in the Department of Dermatology at Northwestern University's Feinberg School of Medicine. He graduated from Yale for both undergrad and medical school and did his residency at Columbia University. He has also earned an MSCI from Northwestern and an MBA from their Kellogg School of Management. Dr. Alam has served as president of the Dermatologic Surgery Society, the American Society of Laser Medicine, and on the editorial board of the Journal of the American Academy of Dermatology. He is an accomplished author, with over 400 peer-reviewed scientific publications.(00:41) Introducing Dr. Murad Alam(03:20) Understanding Dermatology and Dermatologic Surgery(04:18) Types and Causes of Skin Cancer(11:46) Treatment Options for Skin Cancer(18:27) Advancements in Skin Cancer Treatment(22:10) Artificial Intelligence in Dermatology(26:33) When to See a Dermatologist(28:26) Improving Surgical and Traumatic Scars(32:42) Skin Tightening Procedures: Ultrasound, Radio Frequency, and Infrared(37:55) Fillers: Types, Techniques, and Safety(48:30) Low Light Therapy: Benefits and Home Devices(54:17) Sunscreen Safety and FDA Recommendations(56:30) Stem Cell TreatmentsIf there are topics that you are interested in learning more about, please visit MichaelJLeeMD.com.If you'd like to receive new episodes as they're published, please follow I'd Love to Know in Apple Podcasts, Spotify, or wherever you get your podcasts. If you enjoyed this episode, please consider leaving a review on Apple Podcasts or Spotify. It really helps others find the show.The information from this podcast does not constitute medical advice and is meant for basic informational purposes only. If you're interested in pursuing any of the therapies, supplements, or medications discussed here, please consult with your physician.Podcast episode production by Dante32.

Interview with Kavita Y. Sarin, MD, PhD, author of Cutaneous Neurofibromas and Quality of Life in Adults With Neurofibromatosis Type 1. Hosted by Adewole S. Adamson, MD, MPP. Related Content: Cutaneous Neurofibromas and Quality of Life in Adults With Neurofibromatosis Type 1

Interview with Kavita Y. Sarin, MD, PhD, author of Cutaneous Neurofibromas and Quality of Life in Adults With Neurofibromatosis Type 1. Hosted by Adewole S. Adamson, MD, MPP. Related Content: Cutaneous Neurofibromas and Quality of Life in Adults With Neurofibromatosis Type 1

Cutaneous lymphoma can be a tricky disease. It is red, flaky and itchy just like allergies can be. If you see an older dog with these lesions, it should be a differential. But, what do you do if you get back a biopsy of cutaneous lymphoma? What if you can't refer the case to an oncologist?Today's post welcomes Rachel Venable, DVM, MS, DACVIM (oncology) to discuss this disease and what you can do to manage them. She is the founder of Pet Cancer Care Consulting which is a teleconsulting service. Dr. Venable talks about diagnosis, prognosis and various treatment protocols regarding cutaneous lymphoma.TIMESTAMPSIntro 00:00What Oncologists See With Epitheliotropic Lymphoma 02:00The Prognosis Of Epitheliotropic Lymphoma 05:45Does Dr. Venable Do Staging? 09:50The Difference Between B-Cell And T-Cell Lymphoma 11:28Walking Through Different Scenarios 12:58The Concern Of Apoquel Neoplasia 19:00Outro 21:44

In this episode of the Oncology Brothers podcast, Dr. Allison Betof Warner from Stanford University joins hosts Drs. Rahul and Rohit Gosain discuss the current standard of care and recent advances in cutaneous melanoma treatment. Key Points Covered: •⁠  ⁠Early Stage Melanoma: Discussion on the standard of care for different stages, including the role of neoadjuvant immunotherapy. •⁠  ⁠Adjuvant Therapy: Controversies and considerations for stage 2 and beyond, including the use of ctDNA as a predictive tool. •⁠  ⁠Neoadjuvant Therapy: Insights into recent trials and the evolving landscape of neoadjuvant treatment for melanoma. •⁠  ⁠Metastatic Stage: Exploration of treatment options, including immunotherapy combinations and BRAF MEK inhibitors. •⁠  ⁠TILS Therapy: Overview of the recent approval of Tumor Infiltrating Lymphocytes (TILS) therapy for melanoma patients. Stay informed on the latest in melanoma treatment by listening to this insightful discussion with Dr. Warner. Don't miss out on valuable insights that can impact patient care and treatment decisions. Subscribe now to the Oncology Brothers podcast for more updates on oncology practices and advancements.   Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

We recently caught up with Peter Lio, MD, a clinical assistant professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine, at the 2024 Society for Pediatric Dermatology Annual Meeting. Lio presented a session on changing the disease course in pediatric atopic dermatitis, alongside Amy Paller, MD. We'll dive into the highlights of their talk, the role of disease progression, and the exciting pipeline ahead.

Interview with Kathryn T. Shahwan, MD, author of Standardizing Retrospective Observational Research in Cutaneous Squamous Cell Carcinoma: Expert Panel Guidelines from ITSCC. Hosted by Adewole S. Adamson, MD, MPP. Related Content: Standardizing Retrospective Observational Research in Cutaneous Squamous Cell Carcinoma

Interview with Kathryn T. Shahwan, MD, author of Standardizing Retrospective Observational Research in Cutaneous Squamous Cell Carcinoma: Expert Panel Guidelines from ITSCC. Hosted by Adewole S. Adamson, MD, MPP. Related Content: Standardizing Retrospective Observational Research in Cutaneous Squamous Cell Carcinoma

John talks with Dr. Keira Barr — a dual board-certified dermatologist, menopause specialist, author of The Skin Whisperer: A Dermatologist Reveals How to Look Younger, Radiate Beauty, and Live the Life You Crave, speaker, educator, skin cancer survivor, wife, and mom. The two discuss the interconnectedness between the mind, body, and skin and the importance of taking a holistic approach to health and wellness. Listen to this episode to learn more: [00:00] - Intro [01:57] - Dr. Keira's background  [04:29] - Dr. Keira's journey into integrative and functional medicine [07:16] - John's perspective on health [09:13] - “The Skin Whisperer” book [15:09] - Skincare audit to assess overall well-being [18:05] - Relationship between stress, inflammation, and immune system [19:14] - NICE (Neuro, Immune, Cutaneous, Endocrine) system [20:38] - Impact of personal authenticity on relationships and health [23:29] - Inflammation and impact on overall health [27:34] - Dr. Keira's plans to collaborate with psychiatrists [31:20] - Study shows 98% of people with skin issues report mental health impacts [32:51] - John's fascination with neuroscience [34:49] - Observing body language to enhance self-awareness and relationships NOTABLE QUOTES: “Your skin is a reflection of your internal health. So, what you see on the surface of your skin is an invitation to get really curious about what's happening in your life.” “Everything in your environment that can impact how your skin functions, how your body functions, and how you function in your skin is in relationship with each other.” “Most people go around thinking there's something wrong with them; I must be broken. And you're not broken. You just maybe have been misinformed. Maybe no one told you. And there's an opportunity to learn.” “Health is really about the integration of mental, emotional, and spiritual well-being.” “What you see on your skin is an invitation from your body to get really curious about what's happening in your life, in your relationships, with the environment that you're in, and the products that you're using.” “Our body has its own language. And the invitation is, can you be open and willing to learn the language of your body? Because that is the key to the kingdom of enhancing your relationships,  relationship with your first year yourself first, and then your relationship with others.” USEFUL RESOURCES: https://drkeirabarr.com  https://www.linkedin.com/in/keirabarr/  https://www.instagram.com/drkeirabarr https://www.facebook.com/drkeirabarr/ https://www.youtube.com/@keirabarr7540 The Skin Whisperer: A Dermatologist Reveals How to Look Younger, Radiate Beauty and Live the Life You Crave - https://a.co/d/b9ocbrG CONNECT WITH JOHN Website - https://thejohnhulen.com  Instagram - https://www.instagram.com/johnhulen  Facebook - https://www.facebook.com/johnhulen  Twitter - https://www.twitter.com/johnhulen   LinkedIn - https://www.linkedin.com/in/johnhulen     YouTube - https://www.youtube.com/channel/UCLX_NchE8lisC4NL2GciIWA  EPISODE CREDITS Intro and Outro music provided by Jeff Scheetz - https://jeffscheetz.com/ 

In this newscast, I look at the parasitic disease, leishmaniasis and the current situation in Colombia.

Dr. Feldman on THE CURSE OF KNOWLEDGE - Doxycycline is better than minocycline - Psychoactive meds in pruritus - Anifrolumab for cutaneous JDM - Want to donate to the cause? Do so here! Donate to the podcast: uofuhealth.org/dermasphere Check out our video content on YouTube: https://www.youtube.com/@dermaspherepodcast and VuMedi!: https://www.vumedi.com/channel/dermasphere/ The University of Utah's Dermatology ECHO: ⁠https://physicians.utah.edu/echo/dermatology-primarycare - ⁠ Connect with us! - Web: ⁠https://dermaspherepodcast.com/⁠ - Twitter: @DermaspherePC - Instagram: dermaspherepodcast - Facebook: https://www.facebook.com/DermaspherePodcast/ - Check out Luke and Michelle's other podcast, SkinCast! ⁠https://healthcare.utah.edu/dermatology/skincast/⁠ Luke and Michelle report no significant conflicts of interest… BUT check out our friends at: - ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge) - ⁠https://www.levelex.com/games/top-derm⁠ (A free dermatology game to learn more dermatology!

Unless you have been under a pile of retention hyperkeratosis, it would be hard to say one has not heard the call to purposefully diversify clinical trial programs to ensure... The post From Cutaneous Microbiota to Clinical Trial Recruitment… Diversity Matters appeared first on JDDonline - Journal of Drugs in Dermatology.

Dr. Jason Crowell talks with Dr. Christopher Gibbons to discuss his paper "Cutaneous Phosphorylated Alpha-Synuclein Deposition in Dementia with Lewy Bodies and Mild Cognitive Impairment."   Show reference:  https://index.mirasmart.com/AAN2024/SearchResults.php?Program_Number=PL4.004

This week's episode will be focusing on cutaneous malignancies other than melanoma including squamous cell skin cancer and basal cell carcinoma. We will go over the important details on staging, diagnosis, & treatment options. 

Maria Adelaida Gomez joins TWiP to discuss her career and the work of her laboratory on understanding the healing process during cutaneous leishmaniasis. Hosts: Vincent Racaniello, Dickson Despommier, Daniel Griffin, and Christina Naula Guest: Maria Adelaida Gomez Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Links for this episode CIDEIM Healing in cutaneous leishmaniasis (J Immunol) Become a patron of TWiP Send your questions and comments to twip@microbe.tv Music by Ronald Jenkees

In today's VETgirl podcast, we interview Dr. Jeff Tinsley from the Animal Dermatology Clinic about how to diagnose and manage dogs with cutaneous adverse food reaction (CAFR). Skin and gastrointestinal (GI) issues are among the most common problems bringing dogs to the veterinary hospital-in fact, a recent clinic survey revealed that nearly 40% of dogs visit the veterinarian because of one of these two complaints-or in some cases both. Do you know what specific clinical signs and patient history typically suggest that you're dealing with a dog with adverse food reactions? What step-by-step diagnostic workup is warranted to rule in or rule out an adverse food reaction? And tune in to find out the most common mistakes made when starting an elimination diet trial!